[go: up one dir, main page]

MA39915B1 - Composés de pladiénolide pyridine et leurs procédés d'utilisation - Google Patents

Composés de pladiénolide pyridine et leurs procédés d'utilisation

Info

Publication number
MA39915B1
MA39915B1 MA39915A MA39915A MA39915B1 MA 39915 B1 MA39915 B1 MA 39915B1 MA 39915 A MA39915 A MA 39915A MA 39915 A MA39915 A MA 39915A MA 39915 B1 MA39915 B1 MA 39915B1
Authority
MA
Morocco
Prior art keywords
methods
pyridine compounds
pladienolide pyridine
pladienolide
compounds
Prior art date
Application number
MA39915A
Other languages
English (en)
Other versions
MA39915A (fr
Inventor
Peter G Smith
Gregg F Keaney
John Wang
Kenzo Arai
Guo Zhu Zheng
Kazunobu Kira
Parcharee Tivitmahaisoon
Nicholas C Gearhart
Yoshihiko Kotake
Satoshi Nagao
Masayuki Miyano
Norio Murai
Silvia Buonamici
Lihua Yu
Eunice Sun Park
Betty Chan
Michael P Thomas
Ermira Pazolli
Kian Huat Lim
Baudouin Gerard
Xiang Liu
Sudeep Prajapati
Sonobe Regina Kanada
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53284528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39915(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA39915A publication Critical patent/MA39915A/fr
Publication of MA39915B1 publication Critical patent/MA39915B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA39915A 2014-05-15 2015-05-13 Composés de pladiénolide pyridine et leurs procédés d'utilisation MA39915B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461993423P 2014-05-15 2014-05-15
EP15727125.5A EP3143016B1 (fr) 2014-05-15 2015-05-13 Composés de pladiénolide pyridine et leurs procédés d'utilisation
PCT/US2015/030464 WO2015175594A1 (fr) 2014-05-15 2015-05-13 Composés de pladiénolide pyridine et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA39915A MA39915A (fr) 2017-03-22
MA39915B1 true MA39915B1 (fr) 2019-05-31

Family

ID=53284528

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39915A MA39915B1 (fr) 2014-05-15 2015-05-13 Composés de pladiénolide pyridine et leurs procédés d'utilisation

Country Status (36)

Country Link
US (1) US9481669B2 (fr)
EP (2) EP3143016B1 (fr)
JP (1) JP6067943B1 (fr)
KR (2) KR101710318B1 (fr)
CN (1) CN107074827B (fr)
AR (1) AR100431A1 (fr)
AU (1) AU2015259237B2 (fr)
BR (1) BR112016026638B1 (fr)
CA (1) CA2947754C (fr)
CL (1) CL2016002835A1 (fr)
CY (1) CY1121550T1 (fr)
DK (1) DK3143016T3 (fr)
ES (1) ES2712401T3 (fr)
HR (1) HRP20190432T1 (fr)
HU (1) HUE041838T2 (fr)
IL (1) IL248529B (fr)
JO (1) JO3668B1 (fr)
LT (1) LT3143016T (fr)
MA (1) MA39915B1 (fr)
ME (1) ME03417B (fr)
MX (2) MX373324B (fr)
MY (1) MY195081A (fr)
PE (1) PE20170384A1 (fr)
PH (1) PH12016502249B1 (fr)
PL (1) PL3143016T3 (fr)
PT (1) PT3143016T (fr)
RS (1) RS58400B1 (fr)
RU (1) RU2707730C2 (fr)
SG (1) SG11201609693XA (fr)
SI (1) SI3143016T1 (fr)
SM (1) SMT201900158T1 (fr)
TR (1) TR201902328T4 (fr)
TW (1) TWI634115B (fr)
UA (1) UA119458C2 (fr)
WO (1) WO2015175594A1 (fr)
ZA (1) ZA201607354B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3344780B1 (fr) 2015-09-01 2021-06-23 Eisai R&D Management Co., Ltd. Variants d'épissage associés à des mutants de sf3b1 néomorphes
CN108473479B (zh) 2015-11-18 2024-05-07 卫材研究发展管理有限公司 普拉二烯内酯吡啶化合物的固态形式和使用方法
MX2019011003A (es) * 2017-03-15 2019-12-16 Eisai R&D Man Co Ltd Mutaciones de empalmosoma y usos de las mismas.
EP3703755B1 (fr) 2017-10-31 2024-07-31 Eisai R&D Management Co., Ltd. Combinaison comprenant au moins un modulateur de complexe d'épissage et au moins un inhibiteur choisi parmi les inhibiteurs de bcl2, les inhibiteurs de bcl2/bclxl, et les inhibiteurs de bclxl et sa utilisation dans le traitement du cancer.
US11926619B2 (en) 2018-04-09 2024-03-12 Eisai R & D Management Co., Ltd. Certain pladienolide compounds and methods of use
SG11202009907XA (en) 2018-04-12 2020-11-27 Eisai R&D Man Co Ltd Pladienolide derivatives as spliceosome targeting agents for treating cancer
EP3801523B1 (fr) * 2018-06-01 2024-09-11 Eisai R&D Management Co., Ltd. Modulateurs d'épissage
IL316090A (en) 2018-06-01 2024-12-01 Eisai R&D Man Co Ltd Antibody-drug conjugates of splicing modulators and methods of use
IL262658A (en) * 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
AU2021284401A1 (en) * 2020-06-05 2023-01-05 Eisai R&D Management Co., Ltd. Anti-BCMA antibody-drug conjugates and methods of use
KR20230104204A (ko) 2020-11-04 2023-07-07 에자이 알앤드디 매니지먼트 가부시키가이샤 골수이형성 증후군(mds)에 대한 바이오마커 및 이를 사용하는 방법
EP4361136A4 (fr) * 2021-06-18 2025-08-13 Univ Cordoba Composé pour le traitement du glioblastome
CN113876771B (zh) * 2021-11-12 2022-09-23 中国医学科学院基础医学研究所 一种靶向pabpc1的小分子药物及其在慢性髓系白血病中的应用
WO2023131866A1 (fr) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarqueurs pour le syndrome myélodysplasique (mds) et leurs méthodes d'utilisation
JPWO2024101298A1 (fr) 2022-11-07 2024-05-16

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312681B (en) 2001-02-01 2009-08-01 Novel physiologically active substance
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
KR101285695B1 (ko) 2002-07-31 2013-07-12 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 생리 활성 물질
WO2004011459A1 (fr) 2002-07-31 2004-02-05 Mercian Corporation Nouvelle substance active sur le plan physiologique
WO2004037212A2 (fr) 2002-10-24 2004-05-06 Sepracor, Inc. Compositions contenant des derives du zopiclone, et leurs procedes de preparation et d'utilisation
KR20050086873A (ko) 2002-11-29 2005-08-30 메루샹가부시키가이샤 매크로라이드계 화합물의 제조 방법
US7932083B2 (en) 2003-11-27 2011-04-26 Mercian Corporation DNA participating in hydroxylation of macrolide compound
CA2552553C (fr) 2003-11-28 2015-01-06 Kanagawa Academy Of Science And Technology Methode de detection, diagnostic et remede contre le cancer du foie
JPWO2006003706A1 (ja) 2004-07-02 2008-04-17 株式会社プラスワンテクノ 組み合わせ計量技術
ATE538203T1 (de) 2004-07-20 2012-01-15 Eisai R&D Man Co Ltd Für an der biosynthese von pladienolid beteiligtes polypeptid codierende dna
TW200716744A (en) * 2005-05-26 2007-05-01 Eisai R&D Man Co Ltd Genetically modified microorganism and process for production of macrolide compound using the microorganism
CN102010403A (zh) 2005-10-13 2011-04-13 卫材R&D管理有限公司 普拉二烯内酯b和普拉二烯内酯d的全合成
JPWO2008111464A1 (ja) * 2007-03-05 2010-06-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スプライシング異常を指標とする抗ガン剤の作用検定方法
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives

Also Published As

Publication number Publication date
UA119458C2 (uk) 2019-06-25
KR101710318B1 (ko) 2017-02-24
SI3143016T1 (sl) 2019-04-30
SMT201900158T1 (it) 2019-05-10
ES2712401T3 (es) 2019-05-13
PH12016502249B1 (en) 2023-12-13
BR112016026638B1 (pt) 2022-08-02
RU2707730C2 (ru) 2019-11-29
CN107074827B (zh) 2020-12-18
EP3514154A1 (fr) 2019-07-24
CY1121550T1 (el) 2020-05-29
MY195081A (en) 2023-01-09
MX373324B (es) 2020-05-04
NZ764190A (en) 2023-11-24
US9481669B2 (en) 2016-11-01
IL248529A0 (en) 2016-12-29
CA2947754C (fr) 2024-01-02
EP3143016A1 (fr) 2017-03-22
RS58400B1 (sr) 2019-04-30
JP6067943B1 (ja) 2017-01-25
AU2015259237B2 (en) 2019-08-15
RU2019124012A (ru) 2019-08-12
MX388580B (es) 2025-03-20
BR112016026638A2 (fr) 2017-08-15
TR201902328T4 (tr) 2019-03-21
CL2016002835A1 (es) 2017-04-17
AU2015259237A1 (en) 2016-11-10
KR102146726B1 (ko) 2020-08-21
EP3143016B1 (fr) 2018-12-12
DK3143016T3 (en) 2019-04-08
TW201625596A (zh) 2016-07-16
JO3668B1 (ar) 2020-08-27
IL248529B (en) 2019-11-28
TWI634115B (zh) 2018-09-01
KR20160082256A (ko) 2016-07-08
KR20170021899A (ko) 2017-02-28
CN107074827A (zh) 2017-08-18
PE20170384A1 (es) 2017-05-11
US20150329528A1 (en) 2015-11-19
JP2017505282A (ja) 2017-02-16
MX2016014997A (es) 2017-06-29
HUE041838T2 (hu) 2019-05-28
SG11201609693XA (en) 2016-12-29
PT3143016T (pt) 2019-02-27
WO2015175594A1 (fr) 2015-11-19
PL3143016T3 (pl) 2019-04-30
HRP20190432T1 (hr) 2019-04-19
RU2016148887A (ru) 2018-06-18
ME03417B (fr) 2020-01-20
NZ725603A (en) 2023-11-24
MA39915A (fr) 2017-03-22
MX2020004476A (es) 2021-12-08
LT3143016T (lt) 2019-06-10
PH12016502249A1 (en) 2017-02-06
CA2947754A1 (fr) 2015-11-19
ZA201607354B (en) 2018-05-30
EP3514154B1 (fr) 2022-08-03
RU2016148887A3 (fr) 2018-12-11
AR100431A1 (es) 2016-10-05

Similar Documents

Publication Publication Date Title
EP3504213A4 (fr) Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation
EP3429635A4 (fr) Composés anti-crispr et leurs procédés d'utilisation
MA39915B1 (fr) Composés de pladiénolide pyridine et leurs procédés d'utilisation
EP3359168A4 (fr) Composés thérapeutiques et procédés
EP3380101A4 (fr) Composés inhibiteurs d'eif4-a et procédés associés
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
MA43284A (fr) Composés et leurs méthodes d'utilisation
EP3436030A4 (fr) Récepteurs chimériques et leurs procédés d'utilisation
EP2968440A4 (fr) Composés cytotoxiques et antimitotiques et leurs procédés d'utilisation
EP3307762A4 (fr) Variants de cas9 rapporteurs et leurs procédés d'utilisation
EP3319612A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3319610A4 (fr) Oxystérols et leurs procédés d'utilisation
EP3390624A4 (fr) Polypeptides de modification ciblée modifiés et leurs procédés d'utilisation
EP3298168A4 (fr) Agents réducteurs stabilisés et leurs procédés d'utilisation
EP3377612A4 (fr) Expression fonctionnelle de monooxygénases et procédés d'utilisation
EP3307844A4 (fr) Fluides de forage et leurs procédés d'utilisation
EP3778607C0 (fr) Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
EP3394065A4 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
EP3303435A4 (fr) Hydrofluoroléfines et procédés d'utilisation associés
MA40921A (fr) Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
EP3341027A4 (fr) Complexes de transfection et leurs procédés d'utilisation
EP3341017A4 (fr) Compositions d'immunomodulation et leurs procédés d'utilisation
EP3303436A4 (fr) Hydrofluorooléfines et leurs procédés d'utilisation